Literature DB >> 7970473

Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia.

L Deng1, K Bremme, L O Hansson, M Blombäck.   

Abstract

OBJECTIVE: To evaluate the levels of von Willebrand factor and fibronectin as markers for the severity of endothelial cell injury in preeclampsia.
METHODS: In 63 pregnant women with preeclampsia, the plasma levels of von Willebrand factor and fibronectin were measured as soon as symptoms were detected, at 5 weeks postpartum, and after lactation. They were also compared with levels in 29 normotensive pregnant women. The von Willebrand factor was measured by enzyme-linked immunoassay and fibronectin was measured using an automated immunonephelometric method.
RESULTS: In preeclampsia, the levels of von Willebrand factor and fibronectin were higher than in normal pregnancy samples drawn in the second and third trimesters. The levels of fibronectin were still elevated at 5 weeks postpartum in women with severe preeclampsia. Four patients with severe preeclampsia who were studied frequently had high levels of von Willebrand factor 5 weeks postpartum.
CONCLUSIONS: The increased maternal plasma levels of von Willebrand factor and fibronectin indicate that endothelial stimulation is present during preeclampsia. The high fibronectin values found even 5 weeks after delivery, at least in patients with severe preeclampsia, may indicate an ongoing vascular disease with increased risk for preeclampsia in subsequent pregnancies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7970473

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Prediction and prevention of hypertensive disorders of pregnancy.

Authors:  Akihide Ohkuchi; Chikako Hirashima; Kayo Takahashi; Hirotada Suzuki; Shigeki Matsubara
Journal:  Hypertens Res       Date:  2016-08-18       Impact factor: 3.872

2.  Oxidative stress, gene expression, and protein changes induced in the human placenta during labor.

Authors:  Tereza Cindrova-Davies; Hong-Wa Yung; Jemma Johns; Olivera Spasic-Boskovic; Svitlana Korolchuk; Eric Jauniaux; Graham J Burton; D Stephen Charnock-Jones
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

Review 3.  von Willebrand factor and its relevance to cardiovascular disorders.

Authors:  G Y Lip; A D Blann
Journal:  Br Heart J       Date:  1995-12

4.  Alterations in extracellular matrix components and integrins in patients with preeclamptic nephropathy.

Authors:  H Shiiki; T Nishino; H Uyama; T Kimura; K Nishimoto; T Hashimoto; Y Fujii; K Dohi
Journal:  Virchows Arch       Date:  1996-03       Impact factor: 4.064

5.  Pre-eclampsia: is it all in the placenta?

Authors:  Harbindar Jeet Singh
Journal:  Malays J Med Sci       Date:  2009-01

Review 6.  Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.

Authors:  Camille E Powe; Richard J Levine; S Ananth Karumanchi
Journal:  Circulation       Date:  2011-06-21       Impact factor: 29.690

Review 7.  Oxidative stress in preeclampsia and the role of free fetal hemoglobin.

Authors:  Stefan R Hansson; Åsa Nääv; Lena Erlandsson
Journal:  Front Physiol       Date:  2015-01-13       Impact factor: 4.566

8.  Proteomics and Metabolomics Profiling of Platelets and Plasma Mediators of Thrombo-Inflammation in Gestational Hypertension and Preeclampsia.

Authors:  Luiz Gustavo N de Almeida; Daniel Young; Lorraine Chow; Joshua Nicholas; Adrienne Lee; Man-Chiu Poon; Antoine Dufour; Ejaife O Agbani
Journal:  Cells       Date:  2022-04-07       Impact factor: 7.666

9.  Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes.

Authors:  Henry Adekola; Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Zhong Dong; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.